Mercer Global Advisors’s Royalty Pharma RPRX Stock Holding History

Mercer Global Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.73M	Buy	66,553 +25,047	+60%	+$1.3M	﹤0.01%	1012
2026 Q1	$1.99M	Buy	41,506 +24,329	+142%	+$1.07M	﹤0.01%	1198
2025 Q4	$664K	Buy	17,177 +3,452	+25%	+$132K	﹤0.01%	1684
2025 Q3	$484K	Buy	13,725 +5,999	+78%	+$217K	﹤0.01%	1773
2025 Q2	$278K	Buy	7,726 +273	+4%	+$9.04K	﹤0.01%	1888
2025 Q1	$217K	Buy	+7,453	New	+$236K	﹤0.01%	1922
2024 Q1	–	Sell	-22,925	Closed	-$644K	–	2124
2023 Q4	$644K	Buy	22,925 +1,695	+8%	+$46.6K	﹤0.01%	1177
2023 Q3	$576K	Buy	+21,230	New	+$631K	﹤0.01%	1184

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's RPRX Position: Q2 2026 in Review

Mercer Global Advisors increased its Royalty Pharma (RPRX) stake by 60% in Q2 2026, buying an estimated $1.3M and bringing the position to 66,553 shares worth $3.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Mercer Global Advisors first reported a position in RPRX in Q3 2023 and has held it in 8 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Mercer Global Advisors held 66,553 shares of Royalty Pharma worth $3.73M as of Q2 2026.
Mercer Global Advisors bought 25,047 Royalty Pharma shares in Q2 2026, an estimated $1.3M.
Royalty Pharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1012 holding.
Mercer Global Advisors first reported a position in Royalty Pharma in Q3 2023 and has held it in 8 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.